Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J LORD

Showing results (491-500 of 511) with videos related to

Pageof 52
Sort By:
The Journal of Pathology|February 25, 2012
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancersRachael Natrajan, Alan Mackay, Maryou B Lambros, et al.
Cancer Research|February 18, 2026
LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular CarcinomaRenée L Flaherty, Flavia Hughes, George Sflomos, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Nature Medicine|July 4, 2018
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cellsMara Vinci, Anna Burford, Valeria Molinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancerE Harvey-Jones, M Raghunandan, L Robbez-Masson, et al.
Nature Genetics|July 31, 2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress responsePhilip Bland, Harry Saville, Patty T Wai, et al.
Molecular Cancer Therapeutics|July 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor CombinationsAnh Minh Tran Huynh, Jonathan T Lei, Rachel Brough, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancerK Van Baelen, E Sawyer, J Van Cauwenberge, et al.
Nature Genetics|August 9, 2011
Germline mutations in RAD51D confer susceptibility to ovarian cancerChey Loveday, Clare Turnbull, Emma Ramsay, et al.
Journal of Gastroenterology and Hepatology|January 23, 2015
Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinomaDavid C Whiteman, Mark Appleyard, Farzan F Bahin, et al.
Pageof 52

Showing results (491-500 of 511) with videos related to

Sort By:
Pageof 52
The Journal of Pathology|February 25, 2012
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancersRachael Natrajan, Alan Mackay, Maryou B Lambros, et al.
Cancer Research|February 18, 2026
LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular CarcinomaRenée L Flaherty, Flavia Hughes, George Sflomos, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Nature Medicine|July 4, 2018
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cellsMara Vinci, Anna Burford, Valeria Molinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancerE Harvey-Jones, M Raghunandan, L Robbez-Masson, et al.
Nature Genetics|July 31, 2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress responsePhilip Bland, Harry Saville, Patty T Wai, et al.
Molecular Cancer Therapeutics|July 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor CombinationsAnh Minh Tran Huynh, Jonathan T Lei, Rachel Brough, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancerK Van Baelen, E Sawyer, J Van Cauwenberge, et al.
Nature Genetics|August 9, 2011
Germline mutations in RAD51D confer susceptibility to ovarian cancerChey Loveday, Clare Turnbull, Emma Ramsay, et al.
Journal of Gastroenterology and Hepatology|January 23, 2015
Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinomaDavid C Whiteman, Mark Appleyard, Farzan F Bahin, et al.
Pageof 52